- BioPharm International-11-01-2002
- Volume 15
- Issue 11
You Have Failed . . . A Case Study in Warning Letter Remediation
by Joseph Noferi, Edward R. Arling, Ralph L. Dillon, and Mikael Blomqvist, Pharmacia An FDA Warning Letter can be a business disaster. This case study tracks a company from receipt of an FD 483 ? that did not find contamination, but only the potential for contamination ? to 18 months later when the facility received a clean bill of health. What it did to get there ? and what it learned ? may keep your site from losing its operating freedom.
Articles in this issue
almost 23 years ago
Inside Washington: Major Changes Ahead for FDAalmost 23 years ago
Bioinformatics Databases ? Questions of Copyrightalmost 23 years ago
European Editor's Report ? An Industry Comes of Agealmost 23 years ago
Guest Editorial: Back to the Beginningalmost 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.